StreetInsider.com News Articles

Baird Reiterates Outperform Rating on Spyre (SYRE)

Wed, 09 Sep 2026 05:40:18 -0400

Baird analyst Colleen Kusy reiterated an Outperform rating and $116.00 price target on Spyre (NASDAQ: SYRE).

The analyst comments "Incrementally positive on SPY003 results. SPY003's positive data in ulcerative colitis does not come as much of a surprise, given the IL-23 inhibitor mechanism has been clinically validated by multiple other assets, but does continue to build on the body of data supporting Spyre's extended-interval treatment options for IBD. The most meaningful data for the core thesis will come in 2027 when we see combination data across Spyre's three mechanisms of focus (α4β7, TL1A, IL-23) in a larger, placebo-controlled study (SKYLINE Part

Spyre's SPY003 meets primary endpoint in Phase 2 UC trial

Tue, 08 Sep 2026 08:04:23 -0400

Spyre Therapeutics (NASDAQ: SYRE) reported 12-week induction data from Part A of its Phase 2 SKYLINE trial showing that SPY003, an investigational anti-IL-23 antibody, met its primary endpoint in patients with moderately-to-severely active ulcerative colitis (UC).

SPY003 produced a statistically significant 10.0-point reduction from baseline in Robart's Histopathology Index (RHI) score at Week 12 (p<0.0001). Secondary endpoints showed a clinical remission rate of 20% by modified Mayo Score and an endoscopic improvement rate of 30%. The modified Mayo Score declined by 3.5 points.

The trial's study population included 41% advanced therapy-exposed participants, a mean disease duration of 7.1 years, and a mean

Spyre's SPY003 meets primary endpoint in Phase 2 UC trial

Tue, 08 Sep 2026 08:04:23 -0400

The trial's study population included 41% advanced therapy-exposed participants, a mean disease duration of 7.1 years, and a mean

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

Tue, 08 Sep 2026 08:00:00 -0400

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score

Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30%

SPY003 was well tolerated with a safety profile consistent with the IL-23 class

SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYLINE Part B evaluating pairwise combinations of these components is enrolling with topline induction data expected in 2027

WALTHAM, Mass., Sept.

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

Tue, 08 Sep 2026 08:00:00 -0400

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score

Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30%

SPY003 was well tolerated with a safety profile consistent with the IL-23 class

WALTHAM, Mass., Sept.

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences:

Event: Citi 2026 BioPharma Back to School Conference – New York
Date: Wednesday, September 9, 2026
Fireside Time: 10:00 am ET

Event: Wells Fargo 21st Annual Healthcare Conference – Boston
Date: Thursday, September 10, 2026
Fireside Time: 8:00

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

Event: Citi 2026 BioPharma Back to School Conference – New York
Date: Wednesday, September 9, 2026
Fireside Time: 10:00 am ET

Event: Wells Fargo 21st Annual Healthcare Conference – Boston
Date: Thursday, September 10, 2026
Fireside Time: 8:00

Spyre (SYRE) PT Lowered to $116 at Baird

Thu, 27 Aug 2026 06:19:22 -0400

Baird analyst Colleen Kusy lowered the price target on Spyre (NASDAQ: SYRE) to $116.00 (from $120.00) while maintaining a Outperform rating.

Guggenheim Reiterates Buy Rating on Spyre (SYRE)

Thu, 27 Aug 2026 02:20:08 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $130.00 price target on Spyre (NASDAQ: SYRE)

The analyst comments: “Yesterday, Spyre announced topline results for the Phase II SKYWAY-RA program. In short, SPY072/TL1A showed profound evidence of target engagement and stat-sig and/or numerically greater efficacy improvement over placebo (i.e., ACR20/50/70 and ΔDAS28-CRP) across both doses in both TNF-naive & TNF-exp RA patients. Safety was consistent within the known TL1A profile to-date, with no drug-induced SAEs. However, the magnitude of effect hasn't met SYRE's internal bar to justify prioritizing SPY072 monotherapy development, and thus, the company will not advance the RA program

Spyre (SYRE) Reiterated at Buy by Stifel on Topline Results From RA PoC Sub-Study

Wed, 26 Aug 2026 07:28:52 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $123.00 price target on Spyre (NASDAQ: SYRE).

The analyst commented, "SYRE announced topline results from the RA PoC sub-study, which while hitting stats on some endpoints/doses, did not achieve a competitive effect size (<1pt delta on DAS-28CRP) to support monotherapy development (safety in-line). Additional PoC datasets in axSpA and PsA are on track for 4Q26. Bottom line, we see broader TL1A indication expansion as orthogonal to our core UC combo thesis for SYRE--Ph2 data on track for next year and still representative of the majority of today's current valuation. While we expect

After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO

Tue, 25 Aug 2026 16:49:08 -0400

(Updated - August 25, 2026 4:49 PM EDT)

Tue, 25 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26974650.html

Form 8-K Spyre Therapeutics, Inc. For: Aug 25

Tue, 25 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26974650.html

Spyre RA drug trial misses internal bar despite some efficacy

Tue, 25 Aug 2026 16:01:16 -0400

Spyre Therapeutics (NASDAQ: SYRE) announced topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial evaluating SPY072, a TL1A inhibitor, saying the results did not meet the company's internal threshold to advance SPY072 as a monotherapy in rheumatoid arthritis.

Both doses of SPY072 showed statistically significant benefits versus placebo on one or more endpoints at Week 12. The low dose met the primary endpoint, a change from baseline in DAS28-CRP, with a score of -1.9 compared to -1.3 for placebo. The high dose showed a nominally significant ACR20 response rate of 63% versus 43% for placebo, and the

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Tue, 25 Aug 2026 16:01:00 -0400

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)

SPY072 was well tolerated with rates of adverse events comparable to placebo

Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components

Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Tue, 25 Aug 2026 16:01:00 -0400

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)

SPY072 was well tolerated with rates of adverse events comparable to placebo

Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components

Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for